Clinical Trials Browser

Phase 3 × Hereditary Sensory and Autonomic Neuropathies × Rituximab × Clear all

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

13 enrolled 10 charts 1 FDA

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies